New York TimesJ&J Gains Viral Therapies in $1.75 Billion Alios AcquisitionBusinessweekJohnson & Johnson (JNJ:US), the biggest maker of consumer health products, said it will acquire Alios BioPharma Inc., a developer of viral disease therapies. J&J will pay $1.75 billion in cash for closely held Alios, according to a statement today.